Search alternatives:
significant processes » significant progress (Expand Search), significant promise (Expand Search), significant increases (Expand Search)
processes decrease » progressive decrease (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
significant processes » significant progress (Expand Search), significant promise (Expand Search), significant increases (Expand Search)
processes decrease » progressive decrease (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
-
61
-
62
-
63
-
64
PRISMA flow chart of the screening process.
Published 2025“…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
-
65
-
66
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…(F-G) Representative western blots and summarized bar graph showed EVO significantly increased protein expression of SM22α and decreased RUNX2 in CER treated P<sub>i</sub>-induced VSMCs. …”
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80